Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5%
Information source: Bp Consulting, Inc
Information obtained from ClinicalTrials.gov on February 12, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Acute Pseudophakic Cystoid Macular Edema
Intervention: Bromfenac (Drug); Ketorolac (Drug); Diclofenac (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: Bp Consulting, Inc Official(s) and/or principal investigator(s):
David Rho, MD, Principal Investigator, Affiliation: Soll Eye Associates
Overall contact:
Michelle Chabot, Phone: 714-246-9581, Email: michelle_bpconsulting@yahoo.com
Summary
To compare bromfenac 0. 09%, diclofenac sodium 0. 1%, and ketorolac tromethamine 0. 5%
ophthalmic solutions for the treatment of acute pseudophakic CME after cataract surgery.
Clinical Details
Study design: Treatment, Randomized, Open Label, Parallel Assignment
Primary outcome: Acute Pseudophakic Cystoid Macular Edema
Secondary outcome: Visual Acuity
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients must be diagnosed with acute pseudophakic CME within 12 months of cataract
surgery
- Males and females 18 years and older
- Able to provide written informed consent
Exclusion Criteria:
- Complicated cataract surgery, particularly posterior capsule rupture and vitreous
loss
- Pre-Existing macular pathology, including macular edema, macular scar, macular hole,
or macular pucker
- History of Uveitis
- Ipsilateral intraocular surgery prior to cataract surgery
- CME greater than one year duration
Locations and Contacts
Michelle Chabot, Phone: 714-246-9581, Email: michelle_bpconsulting@yahoo.com
Soll Eye Associates, Philadelphia, Pennsylvania 19124, United States; Recruiting
David Rho, MD, Phone: 215-288-5000, Email: michelle_bpconsulting@yahoo.com
Additional Information
Starting date: January 2008
Ending date: May 2008
Last updated: November 20, 2008
|
